BsAb that targets HER2 (identifies a different epitope than trastuzumab or pertuzumab) and CD3, and preferentially binds to Fcγ receptors [64], resulting in a trifunctional antibody that recognizes T cells, stromal cells, and tumor cells, and has an antitumor effect in HER2-high or HER2-low breast tumors [65]. Here, ERBB2 is linked to neoplasm.